Loading stock data…
TERUMO CORP (4543.T)
TSE¥2,247+35.00 (+1.58%)
Market ClosedLast close Jun 29
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Terumo Corporation in the Healthcare sector is trading at ¥2,247 with a market capitalization of $3.3T. Wall Street consensus targets ¥2,970 (13 analysts), implying a +32.2% move over the next 12 months. The stock is currently 20% below its 52-week high of ¥2,818, remaining 0.5% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +32.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | ¥703.30B↓ | ¥820.21B↓ | ¥921.86B↓ | ¥1.04T |
| Gross Profit | ¥369.34B↓ | ¥417.37B↓ | ¥479.17B↓ | ¥560.67B |
| Operating Income | ¥115.96B↓ | ¥117.33B↓ | ¥140.09B↓ | ¥157.67B |
| Net Income | ¥88.81B↓ | ¥89.33B↓ | ¥106.37B↓ | ¥116.98B |
Peer Comparison
JNJUNHPFE
Fundamentals
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Sol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥3.34T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.58
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Strong income play. Yield provides a meaningful total return floor.
156.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.21%
Volume
Today's trading volume
4.67M
Recent News
Terumo (TSE:4543) Valuation Check After Strong 2026 Earnings And Sharp Share Price Rebound
Terumo (TSE:4543) is back in focus after reporting full year results to March 31, 2026, with sales of ¥1,131,877 million and net income of ¥135,914 million, both higher than a year earlier. See our latest analysis for Terumo. The earnings release has been met with a sharp change in sentiment, with a 24.53% 7 day share price return and a 21.99% 90 day share price return contrasting with a 1 year total shareholder return that declined 9.96%. This suggests short term momentum is building after a...
Why Terumo (TSE:4543) Is Up 24.5% After Stronger Full-Year Earnings Lift Profitability - And What's Next
Terumo Corporation has reported past full-year results for the 12 months to March 31, 2026, with sales rising to ¥1,131.88 billion and net income reaching ¥135.91 billion, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year. The combination of stronger revenue and earnings indicates that Terumo improved its profitability over the period, suggesting that recent operational initiatives and cost controls have been effective. We’ll now...
Oil, China Economic Reports Damp Asian Stock Markets
Asian stock markets sagged on Monday, as the Strait of Hormuz remained closed to oil-tanker traffic,
Did Terumo’s (TSE:4543) New Tata Elxsi Partnership and Bond Shelf Just Reframe Its Investment Narrative?
In March 2026, Terumo Corporation filed a shelf registration for up to ¥200 billion in bonds and, a few days earlier, Tata Elxsi announced the opening of the Terumo–Tata Elxsi Offshore Development Center to support Terumo’s cardiac and vascular solutions worldwide. The creation of this dedicated Offshore Development Center highlights Terumo’s push to combine advanced engineering, AI-enabled software, and regional customization to enhance its cardiac and vascular device portfolio and...
Terumo Record Q3 Highlights OrganOx Integration And Margin Story For Investors
Terumo (TSE:4543) reported record-high revenue and profit for its third quarter. North American demand and contributions from the recently acquired OrganOx business supported the result. The quarter also featured improved profit margins alongside the new revenue high. Terumo, a major medical technology group, is seeing its latest quarter shaped by hospital and procedure volumes, reimbursement trends, and ongoing demand for devices that support cardiovascular and surgical care. The record Q3...